RxDoctor Payments Data

Raymond Carrillo, MD

Nephrology · Salinas, CANPI 1265511273

Payments from drug & device makers

$600in general payments, 2019–2025

Across 24 payments — averaging $25.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$150
  • Travere Therapeutics, Inc.$119
  • Vifor Pharma, Inc.$113
  • GSK$24
  • Calliditas Therapeutics US Inc.$24
  • AstraZeneca$23
  • plus $146 from 8 others

What the payments were for

  • Food & beverage$600100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$600 in reported general payments places this provider in the 35th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$1,363,672
Medicare patients
730
Services billed
39,875

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VeltassaPatiromer Calcium Sorbitex56$56,354
VelphoroSucroferric Oxyhydroxide15$37,712
Sevelamer Carbonate51$17,406
EliquisApixaban13$8,537
Calcium Acetate70$6,092
Cinacalcet Hcl18$4,156
Ultra-Fine Short Pen NeedlePen Needle, Diabetic25$1,414
Bumetanide25$882
Hydralazine Hcl61$845
Amlodipine Besylate97$811
Doxazosin Mesylate24$726
Tamsulosin Hcl54$637
Furosemide84$597
Losartan Potassium62$484
Nifedipine ErNifedipine11$444

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$19$37,71215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,341 nephrology providers in California.

Other nephrology in Salinas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →